Trials / Recruiting
RecruitingNCT04286841
The Real World Study of Neoadjuvant Immunotherapy in Early Stage NSCLC in China
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 100 (estimated)
- Sponsor
- Guangdong Association of Clinical Trials · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Several published clinical trials have shown the superiority of immunotherapy in neoadjuvant setting. Here we conducted this real world study to see whether neoadjuvant immunotherapy would bring MPR and survival benefits in NSCLC, for example, single agent immunotherapy or immunotherapy combination with chemotherapy. Furthermore biomarker analysis would be also performed to achieve personalized neoadjuvant immunotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Immunotherapy | Patients in this group should be histologically confirmed potentially resectable NSCLC with stage II-IIIA. Furthermore patients would receive either single agent immunotherapy or immunotherapy combined with chemotherapy. |
Timeline
- Start date
- 2019-05-01
- Primary completion
- 2022-12-01
- Completion
- 2029-12-01
- First posted
- 2020-02-27
- Last updated
- 2020-02-27
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04286841. Inclusion in this directory is not an endorsement.